NCT07104149 - Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Female, Age ≥ 18 Years OldNo Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/ImmunotherapyECOG Score of 0-1Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable LesionSufficient Organ FunctionThe Result of the Urine or Serum Pregnancy Test for the Subject is NegativeSubjects Should Take Contraceptive MeasuresLocally Advanced Cervical CancerExpected Survival Time >6 Months

Interventions

DRUG

Cadonilimab combined with cisplatin

Neoadjuvant chemotherapy plus cadonilimab for locally advanced cervical cancer

Trial Locations (1)

450000

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors

collaborator

Second Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Henan Provincial People's Hospital

OTHER

lead

The First Affiliated Hospital of Zhengzhou University

OTHER